key: cord-0932540-qeelpntq
authors: Li, Can; Chen, Yan-Xia; Liu, Fei-Fei; Lee, Andrew Chak-Yiu; Zhao, Yan; Ye, Zhan-Hong; Cai, Jian-Piao; Chu, Hin; Zhang, Rui-Qi; Chan, Kwok-Hung; Chiu, Kelvin Hei-Yeung; Lung, David Christopher; Sridhar, Siddharth; Hung, Ivan Fan-Ngai; To, Kelvin Kai-Wang; Zhang, Anna Jin-Xia; Chan, Jasper Fuk-Woo; Yuen, Kwok-Yung
title: Absence of vaccine-enhanced disease with unexpected positive protection against SARS-CoV-2 by inactivated vaccine given within three days of virus challenge in Syrian hamster model
date: 2021-01-30
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab083
sha: c2a27d0be4c1847e8fb401b3d290b90972015a59
doc_id: 932540
cord_uid: qeelpntq

BACKGROUND: Mass vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ongoing amidst widespread transmission during the Coronavirus Disease 2019 (COVID-19) pandemic. Disease phenotypes of SARS-CoV-2 exposure occurring around the time of vaccine administration have not been described. METHODS: Two-dose (14 days apart) vaccination regimen with a formalin-inactivated whole virion SARS-CoV-2 in golden Syrian hamster model was established. To investigate the disease phenotypes of a one-dose regimen given 3 days prior (D-3), 1 (D1) or 2 (D2) days after, or on the day (D0) of virus challenge, we monitored the serial clinical severity, tissue histopathology, virus burden, and antibody response of the vaccinated hamsters. RESULTS: The one-dose vaccinated hamsters had significantly lower clinical disease severity score, body weight loss, lung histology score, nucleocapsid protein expression in lung, infectious virus titres in the lung and nasal turbinate, inflammatory changes in intestines and a higher serum neutralizing antibody or IgG titre against the spike receptor-binding domain or nucleocapsid protein when compared to unvaccinated controls. These improvements were particularly noticeable in D-3, but also in D0, D1 and even D2 vaccinated hamsters to varying degrees. No increased eosinophilic infiltration was found in the nasal turbinate, lung, and intestine after virus challenge. Significantly higher serum titre of fluorescent foci microneutralization inhibition antibody was detected in D1 and D2 vaccinated hamsters at day 4 post-challenge compared to controls despite undetectable neutralizing antibody titre. CONCLUSIONS: Vaccination just before or soon after exposure to SARS-CoV-2 does not worsen disease phenotypes and may even ameliorate infection.

The Coronavirus Disease 2019 pandemic caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected over 90 million people with about 2 million deaths after one year [1] . The high transmissibility of SARS-CoV-2 is attributable to the high viral loads in respiratory specimens at or just before the time of symptom onset [2] , which accounts for high attack rates in indoor settings [3] [4] [5] , and is likely mediated through short-range aerosol transmission in addition to droplet and contact transmission. Although only 15% of SARS-CoV-2 RT-PCR-positive cases develop severe disease leading to respiratory failure [6] , the high incidence of COVID-19 especially during winter has placed enormous burden on healthcare services in many affected areas. While patients with milder disease may be monitored and isolated at home, respiratory support and intensive care treatment are reserved for those hospitalized with severe disease. Unfortunately, monotherapy with repurposed antiviral agents, such as remdesivir, lopinavirritonavir, interferon beta, and hydroxychloroquine, have little or no effect in hospitalized COVID-19 patients with severe disease [7, 8] . Monoclonal antibody cocktails may reduce rates of hospitalization and hasten clearance of viral load when given in early disease, but do not alter outcomes in patients with severe COVID-19 [9, 10] . Similarly, treatment with convalescent plasma in randomized clinical trial only improved the clinical status of elderly with mild COVID-19 when given within 3 days of symptom onset, and was not effective after hypoxemia developed [11, 12] . Therefore, before sufficient herd immunity is built up by vaccination, strict border controls, social distancing which severely affect schooling, traveling, mental health and socioeconomic activities, extensive testing for case identification and isolation, painstaking contact tracing and quarantine, universal masking and better hand hygiene remain on the long list of expensive, labour intensive and difficult-to-implement epidemiological measures to reduce morbidity and mortality of the COVID-19

pandemic [13] .

A c c e p t e d M a n u s c r i p t 6 While mRNA, chimpanzee adenovirus vectored and inactivated whole virion SARS-CoV-2 vaccines have recently been approved for emergency use in different countries, there are still concerns about the possibilities of vaccine-enhanced disease or antibody-dependent enhancement of disease [14] . Preclinical studies in experimental animals including non-human primates have so far not demonstrated such deleterious complications when the virus challenge was given weeks after a full course of vaccination [15] [16] [17] . However, data on the outcomes when the vaccine is given in close temporal juxtaposition to SARS-CoV-2 infection, when vaccine-induced antibodies are still undetectable or of low avidity, are not available. Vaccine-enhanced diseases were reported in patients who developed atypical measles or severe respiratory syncytial virus infection after being given formalin inactivated whole virion vaccines which induce a T helper-2 immune response with relatively low levels of poorly neutralizing antibodies of poor avidity [18, 19] . Moreover, antibodydependent enhancement of disease was suspected to worsen SARS-CoV-1 and other virus infections [20] . We have previously established a golden Syrian hamster model which simulates the clinical manifestations of COVID-19 in human [5] . In this study, we analysed the serial clinical scores, body weight loss;, lung and nasal turbinate viral loads and infectious virus titre; tissue virus antigen expression, histopathology score, gene expression level of cytokines and chemokines; and antibody response of hamsters vaccinated with formalin inactivated whole SARS-CoV-2 virion three days before, one to two days after, and on the day of virus challenge.

SARS-CoV-2 HK-13 strain (GenBank accession number: MT835140) was cultured and titrated in African green monkey kidney cells (Vero E6) [21]. To prepare inactivated SARS-CoV-2 whole virion vaccine, SARS-CoV-2 HK-13 inoculated Vero E6 cell culture supernatant collected at 72 hours postinoculation was inactivated with 0.1% (v/v) formalin at 4C for 7 days. The efficiency of inactivation was determined by plaque forming assay on Vero E6 cells as described [22] . The inactivated virus A c c e p t e d M a n u s c r i p t 7 was then purified and concentrated by sucrose gradient ultra-centrifugation at 28,000 rpm [23] .

Collected inactivated virus was tested for total protein amount by bicinchoninic acid protein assay (Thermo Fisher Scientifics) (Supplementary Materials).

Male and female Syrian hamsters at six to eight weeks of age were obtained from the Chinese University of Hong Kong Laboratory Animal Service Centre through the HKU Centre for Comparative Medicine Research. The animals were kept in BSL-2 animal facility with 12-hour light-dark cycle and free access to feed and water [24] . All the animal experimental procedures were approved by the Committee on the Use of Live Animals in Teaching and Research of HKU.

The hamsters were randomly divided into groups. For demonstration of protection by formalininactivated whole virion vaccine given at usual timing, a two-dose-regimen of vaccination at 14-days apart (10 g of total protein in 100 l/ dose) was given as indicated in Figure 1A . For the evaluation of the effect of vaccination close to the time of virus challenge, a one-dose-regimen of vaccination was given 3 days prior to (D-3), immediately before (D0) virus challenge, 1 day or 2 days after virus challenge (D1 and D2, respectively). Animals in control groups were injected with same volume of phosphate buffered saline (PBS) (Supplementary Materials).

To demonstrate vaccine-induced protection, the hamsters were intranasally inoculated with 50 µl of PBS-diluted SARS-CoV-2 (1×10 3 PFUs) at 14 days after second dose of vaccination. This higher virus inoculum was used to check the degree of protection after the two-dose-regimen. To demonstrate A c c e p t e d M a n u s c r i p t 8 the effect of one-dose-regimen of vaccine given just before or after virus challenge, a lower virus inoculum of 50 PFUs of SARS-CoV-2 (HK-13) was intranasally inoculated to achieve a better differentiation of the low level protection induced by such a short interval between vaccination and virus challenge. Body weight and clinical signs of diseases were monitored for 4 to 14 days postchallenge. At day 4 post-challenge (4dpi) when disease is usually severe, 3 hamsters from each group were sacrificed. The nasal turbinate, lung, small intestine, and serum samples were collected for virological and histopathological studies. All experiments involving live SARS-CoV-2 virus were carried out in a biosafety level 3 laboratory.

The methods for determination of lung and nasal turbinate tissue viral load by quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR), fifty percent tissue culture infectious doses (TCID 50 ) assay, mRNA expression levels for cytokines and chemokines in lung homogenates [25, 26] , microneutralization antibody assay [27] and single-cycle virus inhibition fluorescence foci microneutralization antibody (FFMN) assay [28], detection of viral antigen specific IgG in hamster serum by enzyme immunoassay (EIA) [2] , histopathology scoring and immunofluorescence staining were performed as we previously described and elaborated in Supplementary Materials.

All data were analysed with Prism 8.0 (GraphPad Software Inc). One-way ANOVA, Student's t-test or Mann-Whitney test were used to determine the significance of differences among different groups as stated in figure legends. P<0.05 was considered statistically significant.

A c c e p t e d M a n u s c r i p t 9

To validate the standard two-dose-regimen of the formalin-inactivated SARS-CoV-2 whole virion vaccine in the hamster model, we showed that the regimen induced serum IgG antibody against SARS-CoV-2 spike RBD and N, which correlated with the rising neutralizing titre from day 7 to day 28 after first vaccination ( Figure 1B-D) . Good protection against intranasal challenge by 10 3 PFUs of SARS-CoV-2 14-days after the second dose vaccination was evidenced by a significantly lower body weight loss, lower lung viral load and undetectable infectious virus titre at day 4 post-challenge (4dpi) than the PBS control ( Figure 1E -G), and a fast raising high titre of serum neutralizing antibody detected at 4dpi ( Figure 1H ). Notably, limited amount of immunofluorescent N antigen expression were still found in the lungs of vaccinated hamsters (Figure 2A ), however the pulmonary inflammatory infiltrates were only mild and confined to the alveolar wall ( Figure 2B ). In terms of cytokine and chemokine expression in lung, vaccinated hamsters had a significantly higher IFN-α, IFN-γ, IL-6, TNF-α whereas the PBS control had a significantly higher IP-10 and CCL5 ( Figure 2C ). As expected, the histopathological changes of intestinal inflammation, epithelial necrosis and submucosal oedema were much less severe in vaccinated hamsters than PBS controls ( Figure 2D ).

As for the upper respiratory tract, the viral load in nasal turbinate was significantly reduced in vaccinated hamsters by half a log compared to PBS controls ( Figure 3A ), no detectable infectious titre, with decreased inflammation, mucosal necrosis and detachment, and immunofluorescent N expression ( Figure 3B&C ). Serial viral loads in oral swabs were reduced in the vaccinated hamsters, unlike the PBS controls which were still above cut-off between day 8 to day 12 post-challenge ( Figure 3D ).

A c c e p t e d M a n u s c r i p t 10 One-dose vaccination 3 days prior or immediately before virus challenge accelerated neutralizing antibody production and reduced the disease severity in hamster When hamsters were vaccinated 3 days prior to (D-3VP) or immediately before SARS-CoV-2 challenge (D0 VP) ( Figure 4A ), the clinical scores of disease severity were significantly lower in D-3 and D0 vaccinated hamsters (Table 1) . Their weight loss was generally less than the PBS controls though not reaching statistical significance ( Figure 4B ). Interestingly, viral loads of harvested lung and nasal turbinate at 4dpi were significantly lower in D-3 vaccinated hamsters than PBS controls ( Figure 4C ). Furthermore, infectious titres in nasal turbinates and lungs were significantly lower in the D-3 vaccinated and even the D0 vaccinated hamsters ( Figure 4D ). These findings were compatible with lower histology score with less severe inflammation, little vasculitis, and lower amount of N expression in the lungs of D-3 and D0 vaccinated hamsters ( Figure 4E &F; table 1). The inflammatory infiltrate was largely mononuclear cells with no excess eosinophils. As for the expression levels of cytokine and chemokine in lung, significantly higher IFN-α, IFN-γ, IL-1β, and CCL5

were found in D-3 vaccinated and sometimes also D0 vaccinated hamsters, but not IP-10 ( Figure 4G ).

Notably, at 4dpi, serum neutralizing antibody and IgG against SARS-CoV-2 Spike RBD and N were significantly higher in D-3 vaccinated than D0 vaccinated hamsters and PBS control ( Figure 4H ). Using a highly sensitive single-cycle virus inhibition FFMN assay, these 4dpi-sera from D-3 and D0 vaccinated hamsters neutralized SARS-CoV-2 with significant reduction of N-antigen positive fluorescent foci in Vero E6 cells compared to PBS controls (Figure 4 I&J).

When vaccination was given one day (D1VP) or two days (D2VP) after virus challenge, vaccinated hamsters had less weight loss though not reaching statistical significance ( Figure 5A ). The viral load of nasal turbinate on day 4 post-challenge of D1 vaccinated hamsters was significantly lower than PBS control, but no significant differences for lung viral load ( Figure 5B ). More importantly, lung and A c c e p t e d M a n u s c r i p t 11 nasal turbinate showed significantly lower infectious titre in the D1 vaccinated hamsters. Even the D2 vaccinated hamster showed a lower nasal turbinate infectious titre than PBS control ( Figure 5C ).

The expression levels of IFN-α and IFN-γ were significantly higher in the lung of D1 vaccinated hamsters whereas CCL3 and IP-10 were significantly higher in PBS control ( Figure 5D ). The lung histology scores (table 1) , inflammatory infiltration and immunofluorescent N expression were not significantly different ( Figure 5E&F ). No excess eosinophils were noted in the inflammatory infiltrates. Interestingly, serum IgG titres against RBD and N in D1 and D2 vaccinated hamsters were significantly higher than PBS controls ( Figure 5G ) on day 4 post-challenge. These sera significantly reduced N-positive fluorescent foci by FFMN assay ( Figure 5H&I ) despite undetectable titre by conventional neutralization assay. This finding shows that the humoral antibody response observed is due to the vaccine rather than the virus challenge.

As for extra-pulmonary tissue, the degree of intestinal inflammation, epithelial necrosis, submucosal oedema and N antigen expression appeared to be highest in the PBS controls, followed by D2, D1, D0 and D-3 vaccinated hamsters respectively ( Figure 6 ).

Vaccination of hamsters with conventional two-dose-regimen of formalin-inactivated whole virion before virus challenge induced good neutralizing antibody response and protected fully against SARS-CoV-2. Even the one-dose-regimen given within 3 days of SARS-CoV-2 challenge did not result in any vaccine-enhanced diseases. Notably, the vaccinated hamsters had significantly less severe clinical scores and lung histology scores, lower infectious virus titres in lung or nasal turbinate, less N antigen expression, less inflammatory changes in intestines and a higher serum neutralizing antibody or IgG titre against RBD or N. These findings were particularly noticeable in D-3 vaccinated hamsters, A c c e p t e d M a n u s c r i p t 12 but also at various degrees in D0, D1 and even D2 vaccinated hamsters. No increase in eosinophilic infiltration in nasal turbinate or lung was noted after virus challenge.

The effect of whole population vaccination against coronavirus infection is completely unknown to mankind. While the benefit of vaccination is likely to outweigh the physical and psychosocial morbidity, mortality and economic disruption of the COVID-19 pandemic, some unexpected risks of coronavirus vaccines have to be addressed to reassure the general public.

Besides rare complications such as anaphylaxis against vaccine excipients such as polyethylene glycol or immunopathology such as transverse myelitis, potential threats are vaccine-enhanced diseases which have happened with formalin-inactivated whole virion vaccines for measles and respiratory syncytial virus [18, 19] . Another possibility is antibody-dependent disease enhancement, which has been implicated in dengue and SARS-CoV-1 vaccines [20, 29] . Such complications are particularly implicated in vaccines which induce a T-helper 2 response with antibodies having low avidity and poorly neutralizing activity. This situation is possible with inactivated whole virion SARS-CoV-2 vaccines, especially when individuals are exposed to the wild type virus before completing the whole course of the vaccine. Though vaccination studies with non-human primates did not show such vaccine-enhanced diseases with mRNA, adenoviral vector or inactivated whole virion SARS-CoV-2 vaccines, the interval between first dose of vaccination to virus challenge spanned over 3 to 8 weeks which allows the mounting of a good adaptive immune response after affinity maturation of antibody. However, no data on the effect of a single dose of vaccine given within a few days before or after virus challenge is available. In this study, the formalin-inactivated whole virion vaccine was chosen for further evaluation in the hamster model because this vaccine is known to induce a Thelper 2 response with little CD8 cytotoxic or CD4 cell mediated immunity [15] , unlike the mRNA [17] or adenoviral vector vaccines [16] which induced a T helper 1 response with significant CD8 and CD4 lymphocyte mediated immunity.

A c c e p t e d M a n u s c r i p t 13 Vaccine-enhanced disease was not found in our hamster model when the inactivated vaccine is given within a few days before or after virus challenge when antibody affinity maturation or isotypic switching were likely suboptimal. Despite the occurrence of pneumonia after wild-type virus challenge, the disease was not more severe and no excess eosinophilic infiltration was observed as previously reported in formalin inactivated whole virion vaccination for measles and respiratory syncytial virus. Thus, inactivated SARS-CoV-2 vaccines should generally be safe even if vaccinated individuals are exposed to the wild type virus shortly before or after vaccination, a situation which is quite likely to occur when a huge vaccination campaign is held during a pandemic.

The detectable protection by vaccine given 3 days before to 2 days after virus challenge is not completely unexpected. We have previously shown that mice vaccinated with monovalent subunit The funding sources had no role in the study design, data collection, analysis, interpretation or writing of the paper.

This study was partly supported by the Health and Medical Research Fund (COVID190121) of the 

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series

The Coronavirus Disease 2019 pandemic: how does it spread and how do we stop it?

Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility

World Health Organization

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Development of an inactivated vaccine candidate for SARS-CoV-2

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple

Anti-spike IgG causes severe acute lung injury by skewing